Does γ-Hydroxybutyrate Inhibit or Stimulate Central da Release?

References

• Abraini L. H., Raharison L., Rostain J. C. Long-term depression in striatal dopamine release monitored by in vivo voltammetry in free moving rats. Brain Research 1991; 548: 256–259
   PubMedGoogle Scholar
• Aghajanian G. K., Roth R. H. γ-hydroxybutyrate-induced increase in dopamine: localization by fluorescence microscopy. Journal of Pharmacology and Experimental Therapeutics 1970; 175: 131–138
   PubMed Web of Science ®Google Scholar
• Alter C. A., O'Neil S., Marshall J. F. Sensorimotor impairment and elevated levels of dopamine metabolites in the neostriatum occur rapidly after intranigral injection of 6-hydroxy-dopamine or gamma-hydroxybutyrate in awake rats. Neuropharmacology 1984; 23: 309–318
   PubMedGoogle Scholar
• Anden N.-E., Corrodi H., Fuxe K., Ungerstedt U. Importance of nervous impulse flow for the neuroleptic induced increase in amine turnover in central dopamine neurons. European Journal of Pharmacology 1971; 15: 193–199
   PubMed Web of Science ®Google Scholar
• Anden N.-E., Magnussen T., Stock G. Effect of drugs influencing monoamine mechanisms on the increase in brain dopamine produced by axotomy or treatment with gamma hydrox-ybutyric acid. Archives of Pharmacology 1973; 278: 363–372
   PubMedGoogle Scholar
• Anden N-E., Stock G. Inhibitory effect of gamma hydroxybutync acid and gamma aminobutyric acid on the dopamine cells in the substantia nigra. Naunyn Schmiedeberg Archives of Pharmacol. 1973; 279: 89–92
   Google Scholar
• Bettini E., Ceci A., Spinelli R., Samanin R. Neuroleptic-like effects of the I-isomer of fen-fluramine on striatal dopamine release in freely moving rats. Biochemical Pharmacol. 1987; 36: 2387–2391
   PubMed Web of Science ®Google Scholar
• Bergstrom D. A., Bromley S. D., Walters J. R. Dopamine agonists increase pallidal unit activity: attenuation by agonist pretreatment and anaesthesia. European Journal of Pharmacol. 1984; 100: 3–12
   PubMedGoogle Scholar
• Bessman S. P., Fishbein W. N. Gamma hydroxybutyrate, a normal brain metabolite. Nature, London 1963; 200: 1207–1208
   PubMed Web of Science ®Google Scholar
• Brown E. E., Damsma G., Cumming P., Fibiger H. C. Interstitial 3-methoxytyramine reflects striatal dopamine release: an in vivo microdialysis study. Journal of Neurochemistry 1991; 57: 701–707
   PubMedGoogle Scholar
• Bunney B. S., Walter J. R., Roth R. H., Aghajanian G. K. Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity. Journal of Pharmacology and Experimental Therapeutics 1974; 185: 560–571
   Google Scholar
• Bustos G., Roth R. H. Effect of gamma-hydroxybutyrate on the release of monoamines from the rat striatum. British Journal of Pharmacology 1972; 44: 817–820
   PubMed Web of Science ®Google Scholar
• Carlson J. H., Bergstrom D. A., Weick B. G., Walters J. R. Neurophysiological investigation of the effects of the D-1 agonist SKF 38393 on tonic activity of substantia nigra dopamine neurons. Synapse 1987; 1: 411–416
   PubMedGoogle Scholar
• Carroll B., Sharp T. Mania and hyperactivity induced by morphine in the cat. British Journal of Pharmacology 1972; 46: 124–139
   PubMedGoogle Scholar
• Cheramy A., Nieoullou A., Glowinski J. Stimulating effects of gamma-hydroxybutyrate on dopamine release from the caudate nucleus and the substantia nigra of the cat. Journal of Pharmacology and Experimental Therapeutics 1977; 203: 383–393
   Google Scholar
• Chesselet M. F., Chermy A., Reisine T. D., Glowinski J. Morphine and δ-opiate agonists locally stimulate in vivo dopamine release in the cat caudate nucleus. Nature 1981; 291: 320–322
   PubMed Web of Science ®Google Scholar
• Cheaselet M. F., Cheramy A., Reisine T. D., Lubetzki C., Glowinski J., Foumie-Zaluski M. C., Roques B. Effects of various opiates including specific delta and mu agonists on dopamine release from nigrostriatal dopaminergic neurons in vitro in the rat and in vivo in the cat. Life Sciences 1982; 31: 2291–2294
   PubMedGoogle Scholar
• Chrapusta S. J., Karourn F., Egan M. F., Wyatt R. J. γ-butyrolactone-sensitive and insensitive dopamine release, and their relationship to dopamine metabolism in three rat brain regions. European Journal of Pharnnacology 1992; 222: 129–135
   PubMed Web of Science ®Google Scholar
• Clemens J. A., Phebus L. A. Changes in brain chemistry produced by dopaminergic agents: in vivo electrochemical monitoring reveals opposite changes in anaesthetized vs un anaesthetized rats. Brain Research 1983; 267: 183–186
   PubMedGoogle Scholar
• Collin A.-K., Stahle L., Ungerstedt U. Effects of halothane anaesthesia on extracellular levels of DA, DOPAC. HVA and 5-HIAA in rat striatum. Acta Physiologies Scandanovean 1988; 132: 30–39
   Google Scholar
• Costa E., Garattini S. Amphetamines and relecited Compounds, E. Costa, S. Garattini. Raven Press, New York 1970
   Google Scholar
• Cott J., Engel J. Suppression by GAB Aergic drugs of the locomotor stimulation induced by morphine, amphetamine, and apomorphine: evidence for both pre- and post-synaptic inhibition of catecholamine systems. Journal of Neural Transmission 1977; 40: 253–268
   PubMed Web of Science ®Google Scholar
• Creese I., Iversen S. D. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Research 1975; 83: 419–436
   PubMed Web of Science ®Google Scholar
• DeBoer P., Damsma G., Fibiger H. C., Timmerman W., De Vries J. B., Westerink B. H. C. Dopaminergic-cholinergic interactions in the striatum: the critical significance of calcium concentrations in brain microdialysis. Naunyn Schrmiedeherg's Archives of Pharmacology 1990; 342: 528–534
   PubMedGoogle Scholar
• Dhasmana K., Dixit K., Jaja B., Gupta M. Role of central dopaminergic receptors in the manic response of cats to morphine. Psychopharmacology 1972; 24: 380–383
   PubMed Web of Science ®Google Scholar
• Di Giulio A. M., Gropetti A., Cattabeni F., Galli C. L., Maggi A., Algeri S., Ponzio F. The significance of dopamine metabolites in the evaluation of drugs acting on dopaminergic neurons. European Journal of Pharmacology 1978; 52: 201–207
   PubMedGoogle Scholar
• Doherty J. D., Hattox S. E., Snead O. C., Roth R. H. Identification of endogenous γ-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea pig and rhesus monkey brain. Journal of Pharmacology and Experimental Therapeutics 1978; 207: 130–139
   PubMed Web of Science ®Google Scholar
• Dudek B. C., Fanelli R. J. Effects of gamma-butryolactone, amphetamine and haloperidol in mice differing in sensitivity to alcohol. Psychopharmacology 1980; 68: 89–97
   PubMedGoogle Scholar
• Dyck L. E., Kazahoff C. W. Acceleration of the biosynthesis of rat striatal dopamine by incubation and by administration of gamma butyrolactone. Journal of Neuroscience Research 1982; 8: 57–65
   PubMed Web of Science ®Google Scholar
• Ellinwood E. H., Gonzalez A. E., Dougherty G. G. γ-butyrolactone effects on behavior induced by dopamine agonists. Biological Psychiatry 1983; 18: 1023–1032
   PubMedGoogle Scholar
• Feigenbaum J. J., Yanai J., Moon B. H. Differential catecholamine uptake inhibition as a possible mode of action of d-amphetamine induced locomotor activity. Research Communications in Chemistry, Pathology and Pharmacology 1983; 39: 349–352
   PubMedGoogle Scholar
• Feldberg W., Smyth D. G. The C-fragment of lipotropin-a potent analgesic. Journal of Physiology, London 1976; 260: 30–31
   Google Scholar
• Giarman N. J. Antibiotic lactones and synthetic analogs. Thesis for the Ph.D. degree, Yale University 1948
   Google Scholar
• Gessa G. L., Vargiu L., Crabai F., Boero G., Caboni F., Camba R. Selective increase of brain dopamine induced by gamma-hydroxybutyrate. Life Science 1966; 5: 1921–1930
   Google Scholar
• Gessa G. L., Crabai F., Vargiu L., Spano P. F. Selective increase of brain dopamine induced by γ-hydroxybutyrate: study of the mechanism of action. Journal of Neurochemistry 1968; 15: 377–381
   PubMed Web of Science ®Google Scholar
• Gobaille S., Schmidt C., Cupo A., Herbrecht F., Maitre M. Characterization of methion-ine-enkephalin release in the rat striatum by in vivo dialysis: effects of gamma-hydroxybutyrate on cellular and extracellular methionine-enkephalin levels. Neuroscience 1994; 60: 637–648
   PubMedGoogle Scholar
• Godschalk M., Dzoljic M., Bonta I. L. Slow wave sleep and a state resembling absence catalepsy induced by γ-hydroxybutyrate. European Journal of Pharmacology 1977; 44: 105–111
   PubMed Web of Science ®Google Scholar
• Guidotti A., Ballotti P. Relationship between pharmacologicl effects and blood and brain levels of gamma-butyrolactone and gamma-hydroxybutyrate. Biochemical Pharmacology 1976; 19: 883–894
   Google Scholar
• Hamilton M. E., Mele A., Pert A. Striatal extracellular dopamine in conscious vs. anaesthetized rats: effects of chloral hydrate anaesthesic on responses to drugs of different classes. Brain Research 1992; 597: 1–7
   PubMedGoogle Scholar
• Hechler V., Gobaille S., Bourguignon J. J., Maitre M. Extracellular events induced by gamma-hydroxybutyrate in striatum: a micordialysis study. Journal of Neurochemistry 1991; 56: 938–944
   PubMed Web of Science ®Google Scholar
• Hechler V., Peter P., Gobaille S., Bourguignon J. J., Schmitt M., Ehrhardt J. D., Mark J., Maitre M. γ-hydroxybutyrate ligands possess antidopaminergic and neuroleptic-likle activities. Journal of Pharmacology and Experimental Therapeutics 1993; 264: 1406–1414
   PubMed Web of Science ®Google Scholar
• Hutchins D. A., Rayevsky K. S., Sharman D. F. The effect of sodium γ-hydroxybutyrate on the metabolism of dopamine in the brain. British Journal of Pharmacology 1972; 46: 409–415
   PubMedGoogle Scholar
• Imperato A., Di Chiara G. Trans-striatal dialysis coupled to reverse phase high performance chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites. Journal of Neuroscience 1984; 4: 966–977
   PubMedGoogle Scholar
• Imperato A., Di Chiara G. Dopamine release and metabolism in awake animals after systemic neuroleptics as studied by trans-striatal dialysis. Journal of Neuroscience 1985; 5: 297–306
   PubMedGoogle Scholar
• Imperato A., Di Chiara G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. Journal of Pharmacology and Experimental Therapeutics 1986; 239: 219–228
   PubMed Web of Science ®Google Scholar
• Imperato A., Mulas A., Di Chiara G. The D-1 antagonist SCH 23390 stimulates while the D-1 agonist SKF 38393 fails to affect dopamine release in the dorsal caudate of freely moving rats. European Journal of Pharmacology 1987; 142: 177–181
   PubMedGoogle Scholar
• Jouany J. M., Gerard J., Broussollo B., Reynier M., Simone R., Orsetti A., Vermuth C., Baron C. Pharmacologie comparee des sels d'acide butyrique et de l'acide 4-hydroxybutyrique. Agressologie 1960; 1: 417–427
   PubMedGoogle Scholar
• Kehr W., Carlsson A., Lindqvist M., Magnusson T., Atack C. Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. Journal of Pharmacy and Pharmacology 1972; 24: 744–747
   PubMed Web of Science ®Google Scholar
• Kelland M. D., Freeman A. S., Chiodo L. A. Chloral hydrate anaesthesia alters the responsiveness of identified midbrain neurons to dopamine agonist administration. Synapse 1989; 3: 30–37
   PubMedGoogle Scholar
• Laborit H., Jouany J. M., Gerard J., Fabiani F. Généralités concernant l'étude expéri-mentale de l'emploi clinique du gamma hydroxybutyrate de Na. Agressologie 1960; 1: 407–411
   Google Scholar
• Lane R. F., Blaha C. D. Acute thioridazine stimulates mesolimbic but not nigrostriatal dopamine release: demonstration by in vivo electrochemistry. Brain Research 1987; 408: 317–320
   PubMedGoogle Scholar
• Maitre M., Hechler V., Vayer P., Gobaille S., Cash C. D., Schmitt M., Bourguignon J.-J. A specific γ-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvul-sant properties. Journal of Pharmacology and Experimental Therapeutics 1990; 255: 657–663
   PubMed Web of Science ®Google Scholar
• Mamelak M. Gammahydroxybutyrate: An endogenous regulator of energy metabolism. Neuroscience Behavioral Review 1989; 13: 187–198
   PubMed Web of Science ®Google Scholar
• McCown T. J., Mueller R. A., Breese G. R. Effects of anaesthetics and electrical stimulation on nigrostriatal dopaminergic neurons. Journal of Pharmacology and Experimental Therapeutics 1983; 224: 489–493
   PubMedGoogle Scholar
• Menon K., Bieger D., Homykiewicz O. Pharmacological evidence for a selective antidopaminergic action of gamma-hydroxybutyric acid. Journal of Neural Transmission 1976; 39: 177–186
   PubMedGoogle Scholar
• Menon M., Clark W., Schindler A., Alcarez A. A. Studies on the mechanism of the akinetic effects of g-hydroxybutyric acid and 1,4-butanediol. Archives Internationales de Pharmacodynamie et de Therapie 1973; 203: 232–242
   PubMedGoogle Scholar
• Moghaddam B., Bunney B. S. Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. Journal of Neurochemistry 1989; 53: 652–654
   PubMed Web of Science ®Google Scholar
• Morganroth V. H., Walters J. R., Roth R. H. Dopaminergic neurons. Alterations in the kinetic properties of tyrosine hydroxylase after cessation of impulse flow. Biochemical Pharmacology 1976; 25: 655–661
   PubMedGoogle Scholar
• Nielsen J. A., Moore K. E. Effects of chloral hydrate, gamma-butyrolactone, and equithesin on the efflux of dopamine and 5-hydroxytryptamine metabolites into cerebroventricular per-fusates of rats. Journal of Neurochemistry 1982; 39: 235–238
   PubMedGoogle Scholar
• Nieoullan A., Cheramy A., Glowinski J. An adaptation of the push-pull cannula method to study the in vivo release of (3H) dopamine synthesized from (3H) tyrosine in the cat caudate nucleus: effects of various physical and pharmacological treatments. Journal of Neurochemistry 1977; 28: 819–828
   PubMedGoogle Scholar
• Nissbrandt H., Elverfors A., Engberg G. Pharmacologically induced cessation of burst activity in nigral dopamine neurons: Significance for the terminal dopamine efflux. Synapse 1994; 17: 217–224
   PubMed Web of Science ®Google Scholar
• Osborne P. G., O'Connor W. T., Drew K. L., Ungerstedt U. An in vivo characterization of extracellular dopamine and GABA in the dorsolateral striatum of awake, moving, and halothane anaesthetized rats. Journal of Neuoscience Methods, in press
   Google Scholar
• Okuyama S., Shimamura H., Hashimoto S., Aihara H. Electrophysiological and behavioral assessments of dopamine autoreceptor activation to apomorphine in rats. Archives Internationales de Pharmacodynamie et de Therapie 1986; 284: 246–254
   PubMedGoogle Scholar
• Rericic D., Walters J. R. Dopamine in substantia nigra and cortex after γ-butyrolactone treatment. Journal of Pharm. Pharmacology 1976; 28: 527–529
   PubMedGoogle Scholar
• Roffler-Tarlov S., Sharman D. F., Tegerdine P. 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3-methoxy-phenylacetic acid in the mouse striatum: a reflection of intra- and extra-neu-ronal metabolism of dopamine. British Journal of Pharmacology 1971; 42: 343–35
   PubMedGoogle Scholar
• Roth R. H. Effect of anaesthetic doses of gamma-hydroxybutyrate on subcortical concentrations of homovanillic acid. European Journal of Pharmacology 1971; 15: 52–59
   PubMedGoogle Scholar
• Roth R. H. Striatal dopamine and gamma-hydroxybutyrate. International Encyclopedia of Pharmacology and Therapeutics, Section. Pergammon Press, Oxford 1972; 35
   Google Scholar
• Roth R. H. Striatal dopamine and gamma-hydroxybutyrate. Pharmacology and Therapeutics 1976; 2: 71–88
   Google Scholar
• Roth R. H., Doherty J. D., Walters J. R. Gamma-hydroxybutyrate: A role in the regulation of dopaminergic neurons. Brain Research 1980; 189: 556–560
   PubMed Web of Science ®Google Scholar
• Roth R. H., Giarman N. J. Natural occurence of gamma -hydroxybutyrate in mammalian brain. Biochemical Pharmacology 1970; 19: 1087–1094
   Web of Science ®Google Scholar
• Roth R. H., Suhr Y. Mechanism of γ-hydroxybutyrate-induced increase in brain dopamine and its relationship to “sleep”. Biochemical Pharmacology 1970; 19: 3001–3012
   PubMedGoogle Scholar
• Roth R. H., Walters J. R., Aghajanian G. K. Effect of impulse flow on the release and synthesis of dopamine in rat striatum. Frontiers in catecholamine research, E. Usdin, S. Synder. Pergammon Press, New York 1973; 567–574
   Google Scholar
• Rubin B., Giarman N. J. γ-butyrolactone. Yale Journal of Biology and Medicine 1947; 19: 1017–1023
   PubMed Web of Science ®Google Scholar
• Santiago M., Westerink B. H. Characterization and pharmacological responsiveness of dopamine release recorded by microdialysis in the substantia nigra of conscious rats. Journal of Neurochemistry 1991; 57: 738–747
   PubMedGoogle Scholar
• Aratikov A. S., Zamoshchina T. A., Alekseeva L. P., Agarkova V. P. Influence of hydroxy-butyrate on the electroencephalographic effects of fenamin. Bulletin of Experimental Biology and Medicine 1982; 94: 46–49
   Google Scholar
• Avaki H. E., Girault J.-A., Spampinato U., Truong N.-A., Glowinski J., Besson M.-J. Release of newly synthesized 3H-dopamine in the striatum: An adaptation of the push-pull can-nula method to awake restrained and anesthestized rats. Brain Research Bulletin 1986; 16: 149–154
   PubMedGoogle Scholar
• Nead O. C. Gamma-hydroxybutyrate in the monkey. I: Electroencephalographic, behavioral and pharmacokinetic studies. Neurology 1978; 28: 636–642
   PubMedGoogle Scholar
• Pampinato U., Girault J. A., Danguir J., Savaki H. E., Glowinski J., Besson M. J. Apomorphine and haloperidol effects on striatal [3H] dopamine release in anaesthetized, awake, restrained and freely moving animals. Brain Research Bullerin 1986; 16: 1161–1166
   Google Scholar
• Spano P. F., Tagliamonte A., Tagliamonte P., Gessa G. L. Stimulation of brain dopamine synthesis by gamma-hydroxybutyrate. Journal of Neurochemistry 1971; 18: 1831–1836
   PubMed Web of Science ®Google Scholar
• Stahle L., Collin A.-K., Ungerstedt U. Effect of halothane anaesthesia on extracellular levels of dopamine, dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxy-indoleacetic acid in rat striatum: a microdialysis study. Naunyn Schmiedeberg Archives of Pharmacology 1990; 342: 136–140
   Google Scholar
• Stock G., Magnusson T., Anden N. E. Increase in brain dopamine after axotomy or treatment with gammahydroxybutyric acid due to elimination of the nerve impulse flow. Naunyn-Schmiedeberg's Archives of Pharmacology 1973; 278: 347–361
   PubMedGoogle Scholar
• Timmerman W., Westerink B. H. C. Importance of the calcium content infused during microdialysis for the effects induced by D-2 agonists on the release of dopamine in the striatum of the rat. Neuroscience Letters 1991; 131: 93–96
   PubMedGoogle Scholar
• Tolpyschev B. A. Influence of GABA-ergic substances on the effects of caudate nucleus stimulation and fenamin stereotyping in cats. Pharmacology and Toxicology 1980; 43: 140–144
   Google Scholar
• Van Valkenburg C. F. M., Noach E. L., Wijling A. Involvement of the nerve impulse flow in the release of extragranular dopamine. European Journal of Pharmacology 1979; 57: 191–197
   PubMedGoogle Scholar
• Veyer P., Mandel P., Maitre M. γ-Hydroxylate: A possible neurotransmitter. Life Science 1987; 41: 1547–1557
   PubMedGoogle Scholar
• Walters J. R., Roth R. H. Effect of gamma-hydroxybutyrate on dopamine and dopamine metabolites in the rat striatum. Biochemical Pharmacology 1972; 31: 2111–2121
   Google Scholar
• Walters J. R., Roth R. H. Dopaminergic neurons: Drug induced antagonisms of the increase in tyrosine hydroxylase activity produced by a cessation of impulse flow. Journal of Pharmacology and Experimental Therapeutics 1974; 191: 82–91
   PubMed Web of Science ®Google Scholar
• Walters J. R., Roth R. H. Gammahydroxybutyrate: Considerations of endogenous role and therapeutic potential. Neuroregulators and Psychiatric Disorders, E. Usdin, E. Costa. Oxford University Press, New York 1976; 403–415
   Google Scholar
• Walters J. R., Roth R. H., Aghajanian G. K. Dopaminergic neurons: similar biochemical and histochemical effects of g-hydroxybutyrate and acute lesions of the nigro-neostriatal pathway. Journal of Pharmacology and Experimental Therapeutics 1973; 186: 630–339
   PubMed Web of Science ®Google Scholar
• Westerink H. C. Effects of drugs on the formation of 3-methoxytyramine, a dopamine metabolite, in the substantia nigra, striatum, nucleus accumbens and tuberculum olfactorium of the rat. Journal of Pharmacology and Pharmacology 1979; 31: 94–99
   PubMedGoogle Scholar
• Westerink B. H. C., Hofsteede H. M., Damsma G., De Vries J. B. The significance of extracellular calcium for the release of dopamine, acetylcholine and amino acids in conscious rats, evaluated by microdialysis. Naunyn Schmiedeberg's Archives of Pharmacology 1988; 337: 373–378
   PubMedGoogle Scholar
• Westerink B. H. C., Spaan S. J. On the significance of endogenous 3-methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain. Journal of Neurochemistry 1982; 38: 680–686
   PubMedGoogle Scholar
• Wolfson L. I., Sakurada O., Sokoloff L. Effects of γ-butyrolactone on local cerebral glucose utilization in the rat. Journal of Neurochemistry 1977; 29: 777–783
   PubMedGoogle Scholar
• Wood P. L., Alter C. A., Kim H. S. Presynaptic inhibition of nigrostriatal dopamine release in the mouse: lack of cross tolerance between apomorphine, GBL and CGS 107468. Life Science 1988; 42: 1503–1506
   PubMedGoogle Scholar
• Zhang W. Q., Tilson H. A., Nanry K. P., Hudson P. M., Hong J. S., Stachowiak M. K. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Research 1988; 461: 335–342
   PubMedGoogle Scholar
• Zhang W. Q., Tilson H. A., Stachowiak M. K., Hong J. S. Repeated haloperidol administration changes basal release of striatal dopamine and subsequent response to haloperidol challenge. Brain Research 1989; 484: 389–392
   PubMedGoogle Scholar